We help companies connect strategy to execution.
Our Services
Adoption Readiness™ Diagnostic
Commercial Architecture & Strategy
Fractional Commercial Leadership
OUR Audiences
Founders and commercial teams encounter different adoption risks as they move from clinical promise to sustained utilization. Muller Advisory applies a diagnostic-to-execution model to identify where adoption could break, establish the commercial priorities, and provide embedded leadership when additional execution capacity is needed.
Adoption Readiness™ Diagnostic
Evaluates readiness across the Clinical, Commercial, and Financial layers, producing the /45 Adoption Readiness™ Score, a commercial risk map, and prioritized recommendations.
BEST FOR
Companies preparing for launch, a financing round, a board meeting, or a post-pilot reassessment.
Fractional Commercial Leadership
Embedded Fractional CMO or Commercial COO leadership to guide execution, establish operating discipline, align teams and specialists, and maintain accountability against priorities and milestones.
BEST FOR
Companies that need sustained senior commercial leadership without immediately adding a full-time executive.
Commercial Architecture & Strategy
Translates diagnostic findings into positioning, stakeholder strategy, market access priorities, sales enablement, and a sequenced commercialization roadmap.
BEST FOR
Teams that need to address a defined commercialization constraint or prepare the organization for its next stage of growth.
Investors and boards evaluate adoption risk on a different timeline before an investment, during portfolio planning, or as a company approaches a critical commercial decision. Muller Advisory provides an independent view of commercialization readiness using the same MedTech Adoption Architecture™ applied with operating teams.
Adoption Readiness™ Diligence
An independent evaluation of a target or portfolio company’s commercialization readiness, delivered on investment-committee timelines. Findings provide a structured view of where adoption risk is concentrated before capital is committed.
BEST FOR
Investors evaluating a specific MedTech opportunity or preparing for an investment decision.
Board & Portfolio Company Diagnostic
A board-ready assessment supported by the /45 Adoption Readiness™ Score, a commercial risk map, and prioritized recommendations for leadership attention.
BEST FOR
Boards and investors assessing whether a portfolio company is prepared for launch, scale, or additional capital.
Ongoing Portfolio Advisory
Recurring executive advisory for investors, boards, and portfolio-company leadership to monitor adoption priorities, evaluate progress, and support critical commercialization decisions.
BEST FOR
Funds and boards that need sustained commercialization judgment across one or more portfolio companies.
A raise, a launch, a stalled rollout, a board deadline, or a portfolio review?
Let's Talk